180 related articles for article (PubMed ID: 8642290)
1. An insulin peptide that binds an alternative site in class II major histocompatibility complex.
Tompkins SM; Moore JC; Jensen PE
J Exp Med; 1996 Mar; 183(3):857-66. PubMed ID: 8642290
[TBL] [Abstract][Full Text] [Related]
2. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
Xu M; Jackson R; Adams S; Humphreys RE
Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
[TBL] [Abstract][Full Text] [Related]
3. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II.
Hudson KR; Tiedemann RE; Urban RG; Lowe SC; Strominger JL; Fraser JD
J Exp Med; 1995 Sep; 182(3):711-20. PubMed ID: 7650479
[TBL] [Abstract][Full Text] [Related]
4. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding.
Thibodeau J; Cloutier I; Lavoie PM; Labrecque N; Mourad W; Jardetzky T; Sékaly RP
Science; 1994 Dec; 266(5192):1874-8. PubMed ID: 7997881
[TBL] [Abstract][Full Text] [Related]
5. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
Wu S; Gorski J
Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
[TBL] [Abstract][Full Text] [Related]
6. Enterotoxin residues determining T-cell receptor V beta binding specificity.
Irwin MJ; Hudson KR; Fraser JD; Gascoigne NR
Nature; 1992 Oct; 359(6398):841-3. PubMed ID: 1436060
[TBL] [Abstract][Full Text] [Related]
7. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
8. Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor.
Hewitt CR; Lamb JR; Hayball J; Hill M; Owen MJ; O'Hehir RE
J Exp Med; 1992 Jun; 175(6):1493-9. PubMed ID: 1588277
[TBL] [Abstract][Full Text] [Related]
9. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
Karp DR; Long EO
J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
[TBL] [Abstract][Full Text] [Related]
10. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
von Bonin A; Ehrlich S; Malcherek G; Fleischer B
Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
[TBL] [Abstract][Full Text] [Related]
12. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
[TBL] [Abstract][Full Text] [Related]
13. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
14. N-terminal elongation of a peptide determinant beyond the first primary anchor improves binding to H-2 I-Ad and HLA-DR1 by backbone-dependent and aromatic side chain-dependent interactions, respectively.
Bartnes K; Leon F; Briand JP; Travers PJ; Hannestad K
Eur J Immunol; 1999 Jan; 29(1):189-95. PubMed ID: 9933100
[TBL] [Abstract][Full Text] [Related]
15. Analysis of peptide binding patterns in different major histocompatibility complex/T cell receptor complexes using pigeon cytochrome c-specific T cell hybridomas. Evidence that a single peptide binds major histocompatibility complex in different conformations.
Bhayani H; Paterson Y
J Exp Med; 1989 Nov; 170(5):1609-25. PubMed ID: 2553848
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of peptide antigen presentation by a second peptide.
de Kroon AI; McConnell HM
Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8797-801. PubMed ID: 8105466
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of T cells by antigenic peptide complexed with isolated chains of major histocompatibility complex class II molecules.
Nag B; Wada HG; Deshpande SV; Passmore D; Kendrick T; Sharma SD; Clark BR; McConnell HM
Proc Natl Acad Sci U S A; 1993 Feb; 90(4):1604-8. PubMed ID: 7679510
[TBL] [Abstract][Full Text] [Related]
18. More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release.
Daibata M; Xu M; Humphreys RE; Reyes VE
Mol Immunol; 1994 Mar; 31(4):255-60. PubMed ID: 8139580
[TBL] [Abstract][Full Text] [Related]
19. Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells.
Siklodi B; Vogt AB; Kropshofer H; Falcioni F; Molina M; Bolin DR; Campbell R; Hämmerling GJ; Nagy ZA
Hum Immunol; 1998 Aug; 59(8):463-71. PubMed ID: 9712349
[TBL] [Abstract][Full Text] [Related]
20. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M
Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
